Reversible increase of serum activin A levels in women with Graves' disease

J Endocrinol Invest. 2002 Dec;25(11):967-70. doi: 10.1007/BF03344069.

Abstract

The aim of this study was to analyze the serum levels of activin A in hyperthyroid patients with Graves' disease. Serum activin A and FSH levels were measured in a total of 93 females (64 regularly cycling and 29 post-menopausal). Of these, 20 were hyperthyroid patients with Graves disease, 33 were euthyroid goitrous patients (20 had autoimmune thyroiditis AT and 13 only had goiter) representing the internal control group and 40 were healthy subjects representing the external control group. Serum levels of activin A were higher in goitrous patients with AT than in control subjects (p=0.0388). Activin A levels were almost doubled in the cycling and in post-menopausal hyperthyroid women (0.91+/-0.21 vs 0.43+/-0.07 microg/l; p<0.0001 and 0.92+/-0.22 vs 0.48+/-0.24 microg/l; p=0.0001, respectively). In 10 cycling hyperthyroid patients, studied even after methimazole treatment, that increase was substantially reversed, once euthyroidism was attained (p=0.002). These findings indicate that thyroid function and autoimmune processes significantly affect serum levels of activin A in patients with Graves' disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activins / blood*
  • Adult
  • Aged
  • Autoantibodies / blood
  • Female
  • Follicle Stimulating Hormone / blood
  • Graves Disease* / blood*
  • Graves Disease* / drug therapy
  • Graves Disease* / immunology
  • Humans
  • Inhibin-beta Subunits / blood*
  • Methimazole / therapeutic use
  • Middle Aged
  • Postmenopause
  • Thyrotropin / blood
  • Thyroxine / blood

Substances

  • Autoantibodies
  • activin A
  • Activins
  • Methimazole
  • Follicle Stimulating Hormone
  • Thyrotropin
  • Inhibin-beta Subunits
  • Thyroxine